Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis

NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock - Currency: USD

0.901  -0.01 (-1.63%)

After market: 0.9074 +0.01 (+0.71%)

Fundamental Rating

2

Overall LXRX gets a fundamental rating of 2 out of 10. We evaluated LXRX against 555 industry peers in the Biotechnology industry. Both the profitability and financial health of LXRX have multiple concerns. LXRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LXRX has reported negative net income.
LXRX had a negative operating cash flow in the past year.
LXRX had negative earnings in each of the past 5 years.
In the past 5 years LXRX always reported negative operating cash flow.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

LXRX has a Return On Assets (-59.56%) which is comparable to the rest of the industry.
LXRX has a worse Return On Equity (-144.11%) than 61.62% of its industry peers.
Industry RankSector Rank
ROA -59.56%
ROE -144.11%
ROIC N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

LXRX has a Gross Margin of 98.03%. This is amongst the best in the industry. LXRX outperforms 98.02% of its industry peers.
LXRX's Gross Margin has been stable in the last couple of years.
LXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LXRX has been increased compared to 1 year ago.
The number of shares outstanding for LXRX has been increased compared to 5 years ago.
Compared to 1 year ago, LXRX has an improved debt to assets ratio.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

LXRX has an Altman-Z score of -9.56. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.56, LXRX is doing worse than 73.33% of the companies in the same industry.
A Debt/Equity ratio of 0.48 indicates that LXRX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.48, LXRX is not doing good in the industry: 73.69% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -9.56
ROIC/WACCN/A
WACC10.74%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.22 indicates that LXRX has no problem at all paying its short term obligations.
With a Current ratio value of 2.22, LXRX is not doing good in the industry: 73.15% of the companies in the same industry are doing better.
A Quick Ratio of 2.22 indicates that LXRX has no problem at all paying its short term obligations.
LXRX has a worse Quick ratio (2.22) than 71.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 2.22
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

LXRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.55%, which is quite impressive.
The Revenue has grown by 1238.46% in the past year. This is a very strong growth!
Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -37.35% on average per year.
EPS 1Y (TTM)38.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65%
Revenue 1Y (TTM)1238.46%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%11.68%

3.2 Future

The Earnings Per Share is expected to grow by 12.78% on average over the next years. This is quite good.
LXRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 73.16% yearly.
EPS Next Y37.3%
EPS Next 2Y19.69%
EPS Next 3Y18.4%
EPS Next 5Y12.78%
Revenue Next Year53.02%
Revenue Next 2Y5.84%
Revenue Next 3Y63.47%
Revenue Next 5Y73.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LXRX. In the last year negative earnings were reported.
Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as LXRX's earnings are expected to grow with 18.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.69%
EPS Next 3Y18.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (7/3/2025, 7:45:41 PM)

After market: 0.9074 +0.01 (+0.71%)

0.901

-0.01 (-1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners74.87%
Inst Owner Change-22.56%
Ins Owners0.84%
Ins Owner Change0.4%
Market Cap327.23M
Analysts80
Price Target2.63 (191.9%)
Short Float %10.47%
Short Ratio7.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.16%
Min EPS beat(2)29.61%
Max EPS beat(2)30.7%
EPS beat(4)3
Avg EPS beat(4)16.18%
Min EPS beat(4)-7.28%
Max EPS beat(4)30.7%
EPS beat(8)6
Avg EPS beat(8)6.98%
EPS beat(12)9
Avg EPS beat(12)4.55%
EPS beat(16)13
Avg EPS beat(16)6.23%
Revenue beat(2)1
Avg Revenue beat(2)144.65%
Min Revenue beat(2)-12.42%
Max Revenue beat(2)301.73%
Revenue beat(4)1
Avg Revenue beat(4)51.23%
Min Revenue beat(4)-42.95%
Max Revenue beat(4)301.73%
Revenue beat(8)2
Avg Revenue beat(8)51.66%
Revenue beat(12)2
Avg Revenue beat(12)6.99%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.77%
PT rev (3m)-0.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.79%
EPS NY rev (1m)-15.71%
EPS NY rev (3m)-2.85%
Revenue NQ rev (1m)262.01%
Revenue NQ rev (3m)268.68%
Revenue NY rev (1m)76.67%
Revenue NY rev (3m)27.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.48
P/FCF N/A
P/OCF N/A
P/B 2.66
P/tB 4.17
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.09
BVpS0.34
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.56%
ROE -144.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.03%
FCFM N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 2.22
Altman-Z -9.56
F-Score5
WACC10.74%
ROIC/WACCN/A
Cap/Depr(3y)200.97%
Cap/Depr(5y)201.27%
Cap/Sales(3y)447.45%
Cap/Sales(5y)348.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65%
EPS Next Y37.3%
EPS Next 2Y19.69%
EPS Next 3Y18.4%
EPS Next 5Y12.78%
Revenue 1Y (TTM)1238.46%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%11.68%
Revenue Next Year53.02%
Revenue Next 2Y5.84%
Revenue Next 3Y63.47%
Revenue Next 5Y73.16%
EBIT growth 1Y4.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-71.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.43%
OCF growth 3YN/A
OCF growth 5YN/A